NEW YORK — Merck & Co. said Thursday that a combination of niacin and another medicine failed to protect against heart attacks and strokes in a large clinical trial. The drug maker will no longer pursue US approval of the combination therapy.

The trial, which followed more than 25,000 patients over four years, also found a statistically significant increase in the number of patients who suffered serious nonfatal adverse events.